State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 4, 2012, Pages 261-269

  Mori, Keiichiro ^a   Morita, Kiichiro ^b   Shoji, Yoshihisa ^a,b   Matsuoka, Toshimasa ^a,b   Fujiki, Ryo ^a   Uchimura, Naohisa ^a  

^a Department of Neuropsychiatry ^*  (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

atypical antipsychotic drugs; drug na ve schizophrenia; facial affection; P300; trait and state markers

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; OLANZAPINE; PEROSPIRONE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BRAIN DEPTH RECORDING; CATATONIC SCHIZOPHRENIA; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CRYING; DISEASE DURATION; DRUG EFFICACY; DRUG NAIVE SCHIZOPHRENIA; ELECTROENCEPHALOGRAM; EMOTIONALLY CHARGED VISUAL EVENT RELATED POTENTIAL; EVOKED VISUAL RESPONSE; FACIAL EXPRESSION; FEMALE; HEBEPHRENIA; HUMAN; MALE; ONSET AGE; P300 AMPLITUDE; PARANOID SCHIZOPHRENIA; PHOTOGRAPHY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGIC ASSESSMENT; REACTION TIME; SCHIZOPHRENIA; SIGNAL PROCESSING; UNDIFFERENTIATED SCHIZOPHRENIA; VISUAL STIMULATION; WORKING MEMORY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; EMOTIONS; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, VISUAL; FACIAL EXPRESSION; FEMALE; HUMANS; ISOINDOLES; MALE; PHOTIC STIMULATION; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 84861557458     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02345.x     Document Type: Article

References (24)

1. Polich J,. P300 in clinical application: Meaning, method, and measurement. Am. J. EEG Technol. 1991; 31: 201-231.
2. Blackwood D,. P300, a state and a trait marker in schizophrenia. Lancet 2000; 355: 771-772.
3. Mathalon DH, Ford JM, Pfefferbaum A,. Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol. Psychiatry 2000; 47: 434-449.
4. Maeda H, Morita K, Kawamura N, Nakazawa Y,. Amplitude and area of the auditory P300 recorded with eyes open reflect remission of schizophrenia. Biol. Psychiatry 1996; 39: 743-746.
5. Iwanami A, Okajima Y, Isono H, et al,. Effects of risperidone on event-related potentials in schizophrenic patients. Pharmacopsychiatry 2001; 34: 73-79.
6. Gonul AS, Suer C, Coburn K, Ozesmi C, Oguz A, Yilmaz A,. Effects of olanzapine on auditory P300 in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 173-177.
7. Purdon SE, Jones DW, Strip E, et al,. Neuropsychological changes in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry 2000; 57: 249-258.
8. Purdon SE, Malla A, Labelle A, Lit W,. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001; 26: 137-149.
9. Umbricht D, Javitt D, Novak G, et al,. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol. Psychiatry 1998; 44: 716-725.
10. Lang SF, Nelson CA, Collins PF,. Event-related potentials to emotional and neutral stimuli. J. Clin. Exp. Neuropsychol. 1990; 12: 946-958.
11. Johnston WS, Wang XT,. The relationship between menstrual phase and the P3 component of ERPs. Psychophysiology 1991; 28: 400-409.
12. An SK, Lee SJ, Lee CH, et al,. Reduced P3 amplitude by negative facial emotional photographs in schizophrenia. Schizophr. Res. 2003; 64: 123-135.
13. Yamamoto M, Morita K, Waseda Y, et al,. Changes in auditory P300 with clinical remission in schizophrenia; Effects of facial-affect stimuli. Psychiatry Clin. Neurosci. 2001; 55: 347-352.
14. Ueno T, Morita K, Shoji Y, et al,. Recognition of facial expression and visual P300 in schizophrenic patients: Differences between paranoid type patients and non-paranoid patients. Psychiatry Clin. Neurosci. 2004; 58: 585-592.
15. Inagaki A, Inada T, Fujii Y, Yagi G,. Dose equivalence of psychotic drugs part XV-dose equivalence of novel neuroleptics: perospirone. Jpn. J. Clin. Psychopharmacol. 2001; 4: 869-870.
16. Shirazi-Southall S, Rodriguez DE, Nomikos GG,. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002; 26: 583-594.
17. Kay SR, Opler LA, Fiszbein A,. (translated by Yamada H, Matsui K, Kikumoto K) Positive and Negative Syndrome Scale (PANSS) Rating Manual. Seiwa Shoten Publishers, Tokyo, 1991.
18. Kane JM, Leucht S, Carpenter D, et al,. The expert consensus guideline series optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003; 64: 1-100.
19. Kutas M, McCarthy G, Donchin E,. Augmenting mental chronometry: The P300 as measure of stimulus evaluation time. Science 1997; 197: 792-795.
20. Strik WK, Dierks T, Maurer K,. Amplitudes of auditory P300 in remitted and residual schizophrenics: Correlations with clinical features. Neuropsychobiology 1993; 27: 54-60.
21. Polich J,. Updating P300: An integrative theory of P3a and P3b. Clin. Neurophysiol. 2007; 118: 2128-2148.
22. Uetsuki M,. Estimation of premorbid IQ by JART in schizophrenia. Seishin Igaku (Clin. Psychiatry) 2006; 48: 15-22 (in Japanese).
23. Loughland CM, Williams LM, Gordon E,. Visual scan paths to positive and negative facial emotions in an outpatient schizophrenia sample. Schizophr. Res. 2002; 55: 159-170.
24. Minassian A, Granholm E, Verney S, Perry W,. Visual scanning deficits in schizophrenia and their relationship to executive functioning impairment. Schizophr. Res. 2005; 74: 69-79.